Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The global acute myeloid Leukemia treatment market is expected to grow at a CAGR of 11.4% during the forecast period of 2023-2031, driven by the rapidly growing number of Leukemia cases, especially among children.
Acute myeloid Leukemia (AML) refers to the type of blood cancer that develops in bone marrow and spreads throughout the blood, central nervous system, spleen, and other parts of the body, affecting the abnormal production of white blood cells. It is diagnosed by the rapid growth of immature leucocytes known as leukemic blasts. Acute and chronic disease are divided based on the rate of disease development and cell type. AML spreads more quickly than chronic conditions do, necessitating urgent medical care.
The DNA mutation in the stem cells in bone marrow produces platelets, red and white blood cells, but due to the mutation, there is an increase in the production of white blood cells, more than required.
The white blood cells are not fully mature and thus cannot protect and fight properties against harmful microbes. Red blood cells and platelets eventually decrease as the number of white blood cells rises.
The signs and symptoms of AML include fever, pain in bones, weight loss, headaches, shortness of breath, irregular heartbeat, nose/gum bleeding, recurrent infection, difficulty in breathing, and fatigue, among others. Age-related AML development is accompanied by an increase in the incidence of dangerous cytogenetic and molecular abnormalities.
Various tests are required to determine the AML sub-type and acute myeloid Leukemia (AML) status. Some of these tests might have to be repeated after therapy to evaluate the efficacy of the treatment. AML and its sub-types are diagnosed through blood and bone marrow testing; changes in blood cell count, and appearance also aid the diagnosis. There are many pre-treatments testing available in the market, including cardiac tests, blood chemical profiles, and Human Leukocyte Antigen (HLA) type.
There is no permanent cure for ALM as the chances of reoccurrence are relatively high. ALM can be treated by chemotherapy, drug therapy, and radiation therapy.
Acute myeloid Leukemia is most prevalent in High to medium Sociodemographic Index (SDI) regions. The highest incidents of AML per 100,000 population were seen in East Asia, followed by Australia, and Western Europe whereas, the lowest was seen in west sub – Saharan Africa and Central Sub-Saharan Africa.
AML incidence has recently increased in the Asian region, which has led to an increase in clinical trials for new leukemia treatments. According to research by Astellas Pharma Inc., 4,500 patients are diagnosed with AML in Japan each year. In addition, the survey revealed that the prevalence of AML was higher among the elderly population. This illness may place a financial strain on the entire population due to the percentage increase in the geriatric population.
The prevalence of AML over a five-year period was high in low-income Asia Pacific nations and low in high-income Asia Pacific countries, respectively. The Asia Pacific region is made up of nations that are not only economically developing but also seeing significant annual population growth.
As a result, there is a substantial risk of AML occurrence as these countries populations grow. AML is the most common form of Leukemia , accounting for 1% of all cancers. Of Leukemia , the high SDI region had the most death cases. In the medium SDI and low-middle SDI regions, the age-specific mortality rate (ASDR) sharply increased at the same time.
Acute Myeloid Leukemia Treatment Market Segmentations:
Market Breakup by Diagnosis Methods
Market Breakup by Therapy Type
Market Breakup by Treatment Channel
Acute Myeloid Leukemia Treatment Market Breakup by Region
The goal of acute myeloid Leukemia treatment market is to put leukemia into complete remission. Approximately two out of every three AML patients who receive routine induction chemotherapy (chemo), experience remission. This typically indicates that there are no indications or symptoms of the disease, the blood cell counts return to normal ranges, and the bone marrow has less than 5% blast cells.
The actual probability of remission is significantly influenced by an individual's unique prognostic factors, including age and the existence of certain genes or chromosome abnormalities in the Leukemia cells. If remission occurs, the patient is typically given further chemo treatment to kill new Leukemia cells, up to 50% of these patients are likely to go into long-term remission, which is affected by prognostics factors, like age, genes, or chromosomal changes. Stem cell transplant as therapy is of high success and higher risk for the patient.
The patient is considered for the treatment based on age, performance status, exposure to chemotherapy, radiotherapy, ADH organ function. While the morphology, immunophenotype, cytogenetics, and molecular NGS are used to characterise AML.
Chemotherapy remains the main type of treatment for AML and researchers are working on the efficacy and reduced side effects of the therapy. Some new chemo drugs include Sapacitabine, Laromustine, and Guadecitabine.
Stem cell transplant treatment differ based on where the blood-forming stem cells come from. Allogeneic stem cell transplant is the most common form of stem cell transplant, the stem cells come from the donor, closely related to the patient whose tissue type known as HLA type.
In autologous transplants, patients’ own stem cells are removed and stored frozen, while the patient receives the chemotherapy/radiation, and stem cells are put back after the therapy.
Targeted drug therapy is the gene-targeted drug specifically attacking the gene changes in the AML cells.
FLT3 Inhibitors: Leukemia with a gene mutation in the FLT3 gene can be treated with the FDA-approved FLT3 inhibitors Midostaurin, and Gilteritinib, whereas crenolanib is under trials.
IDH Inhibitors: A gene with a mutation in IDH1, IDH2 gene, which blocks cells from maturing. IDH inhibitor drugs include Enasidenib, Ivosidenib.
Histone Deacetylase (HDAC) Inhibitors: HDAC are a relatively new class of anti-cancer drugs that have significant effects on epigenetic or non-epigenetic control, killing cancer cells and causing apoptosis and cell cycle arrest.
BCL-2 Inhibitors: A specific inhibitor of the B-cell lymphoma 2 (Bcl-2) anti-apoptotic protein that may also have pro-apoptotic and anti-cancer properties which include Venetoclax.
Polo-like kinase (Plk) Inhibitors: A family of serine/threonine kinases, also known as polo-like kinases (PLKs), is important at several stages of mitosis. The PLK1 gene has been the focus of most research. It is an exciting target in oncology because it is overexpressed in a variety of cancer types. The majority of PLK1 inhibitors compete with ATP, which includes Alisertib.
Immunotherapy: To fight the cancerous cells, the immune system is boosted in this therapy, which includes Monoclonal antibodies.
The report gives an in-depth analysis of the key players involved in the market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Diagnosis Method||
|Breakup by Therapy Type||
|Breakup by Treatment Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Acute Myeloid Leukemia Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Acute Myeloid Leukemia Treatment Market Market
6.1 Global Acute Myeloid Leukemia Treatment Market Overview
6.2 Global Acute Myeloid Leukemia Treatment Market Analysis
6.2.1 Market Overview
18.104.22.168 Global Acute Myeloid Leukemia Treatment Market Historical Value (2016-2022)
22.214.171.124 Global Acute Myeloid Leukemia Treatment Market Forecast Value (2023-2031)
6.3 Global Acute Myeloid Leukemia Treatment Market by Diagnosis Method
6.3.1 Market Overview
126.96.36.199 Biopsy and Bone Marrow Aspiration
188.8.131.52 Complete Blood Count (CBC) and Differential
184.108.40.206 Philadelphia Chromosome’s Presence
220.127.116.11 Spinal Tap (lumbar puncture) and Cerebrospinal Fluid (CSF) Analysis
18.104.22.168 Immunophenotyping or Phenotyping by Flow Cytometry
22.214.171.124 Polymerase Chain Reaction (PCR)
6.4 Global Acute Myeloid Leukemia Treatment Market by Therapy Type
6.4.1 Market Overview
126.96.36.199 Targeted Drugs
188.8.131.52 Stem/Bone Marrow Transplant
184.108.40.206 Radiation Therapy
6.5 Global Acute Myeloid Leukemia Treatment Market by Treatment Channel
6.5.1 Market Overview
6.6 Global Acute Myeloid Leukemia Treatment Market by Region
6.6.1 Market Overview
220.127.116.11 North America
18.104.22.168.1 Historical Trend (2016-2022)
22.214.171.124.2 Forecast Trend (2023-2031)
126.96.36.199.1 Historical Trend (2016-2022)
188.8.131.52.2 Forecast Trend (2023-2031)
184.108.40.206 Asia Pacific
220.127.116.11.1 Historical Trend (2016-2022)
18.104.22.168.2 Forecast Trend (2023-2031)
22.214.171.124 Latin America
126.96.36.199.1 Historical Trend (2016-2022)
188.8.131.52.2 Forecast Trend (2023-2031)
184.108.40.206 Middle East and Africa
220.127.116.11.1 Historical Trend (2016-2022)
18.104.22.168.2 Forecast Trend (2023-2031)
7 North America Acute Myeloid Leukemia Treatment Market
7.1 United States of America
7.1.1 Historical Trend (2016-2022)
7.1.2 Forecast Trend (2023-2031)
7.2.1 Historical Trend (2016-2022)
7.2.2 Forecast Trend (2023-2031)
8 Europe Acute Myeloid Leukemia Treatment Market
8.1 United Kingdom
8.1.1 Historical Trend (2016-2022)
8.1.2 Forecast Trend (2023-2031)
8.2.1 Historical Trend (2016-2022)
8.2.2 Forecast Trend (2023-2031)
8.3.1 Historical Trend (2016-2022)
8.3.2 Forecast Trend (2023-2031)
8.4.1 Historical Trend (2016-2022)
8.4.2 Forecast Trend (2023-2031)
9 Asia Pacific Acute Myeloid Leukemia Treatment Market
9.1.1 Historical Trend (2016-2022)
9.1.2 Forecast Trend (2023-2031)
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
9.4.1 Historical Trend (2016-2022)
9.4.2 Forecast Trend (2023-2031)
9.5.1 Historical Trend (2016-2022)
9.5.2 Forecast Trend (2023-2031)
10 Latin America Acute Myeloid Leukemia Treatment Market
10.1.1 Historical Trend (2016-2022)
10.1.2 Forecast Trend (2023-2031)
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
11 Middle East and Africa Acute Myeloid Leukemia Treatment Market
11.1 Saudi Arabia
11.1.1 Historical Trend (2016-2022)
11.1.2 Forecast Trend (2023-2031)
11.2 United Arab Emirates
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 South Africa
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
12 Current Scenario Evaluation and Regulatory Framework
12.1 Emerging Therapies and Clinical Trials
12.2 Patent Landscape
12.2.1 Patent Overview
22.214.171.124 Patent Status and Expiry
126.96.36.199 Timelines from Drug Development to Commercial Launch
188.8.131.52 New Drug Application
184.108.40.206.1 Documentation and Approval Process
12.3 Cost of Treatment
12.4 Regulatory Framework
12.4.1 Regulatory Overview
220.127.116.11 US FDA
18.104.22.168 EU EMA
22.214.171.124 INDIA CDSCO
126.96.36.199 JAPAN PMDA
13 Challenges & Unmet Needs
13.1 Treatment Pathway Challenges
13.2 Compliance and Drop-out Analysis
13.3 Awareness and Prevention Gaps
14 Acute Myeloid Leukemia Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Daiichi Sankyo Company, Limited
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.2 Teva Pharmaceutical Industries Ltd.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.3 Sanofi S.A.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.4 Pfizer Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.5 Oncolyze Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.6 Syndax Pharmaceuticals Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.7 AbbVie Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.8 Amgen Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.9 Servier Pharmaceutical LLC
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.10 F. Hoffmann-La Roche Ltd
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.11 Viracta Therapeutics, Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.12 Novartis AG
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.13 Otsuka Holdings Co. Ltd
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
16 Recommendations and Discussion
17 Global Acute Myeloid Leukemia Treatment Drugs Distribution Model (Additional Insight)
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Payment Methods (Additional Insight)
18.1 Government Funded
18.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market is likely to grow at a CAGR of 11.4% during the forecast period of 2023-2031.
Rising cancer prevalence, along with the increased geriatric population in Asia pacific region is expected to drive the growth of the market.
The major regions in the acute myeloid leukemia treatment market include North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share of the market.
The key players in the market include Daiichi Sankyo Company, Limited, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Pfizer Inc., Oncolyze Inc., Syndax Pharmaceuticals Inc., AbbVie Inc., Amgen Inc., Servier Pharmaceutical LLC, F. Hoffmann-La Roche Ltd, Viracta Therapeutics, Inc., Novartis AG, and Otsuka Holdings Co. Ltd., among others.
A DNA mutation in the bone marrow stem cells that create red blood cells, platelets, and infection-fighting white blood cells results in acute myeloid leukemia (AML). The stem cells create far more white blood cells than are required as a result of the mutation.
After receiving the proper induction medication, 60 to 70% of persons with AML might achieve CR status. It is estimated that more than 25% of adults with AML will survive for three or more years and may have a cure (about 45% of those who achieve CR).
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.